Fetal ve erken postnatal serum endoglin düzeylerinin doğum ağırlığı ve maternal preeklampsi ile ilişkisi

Öz

Amaç: Bu çalışmanın amacı fetal ve erken postnatal serum endoglin düzeylerinin fetal büyümedeki rolünü ve maternal preeklampsinin endoglin düzeylerine olan ilişkisini araştırmaktır.
Materyal ve Method: Bu çalışmaya 55 yenidoğan prospektif olarak çalışmaya dahil edildi ve 4 gruba ayrıldı:1)Normal gebelik ve gebelik haftasına göre düşük doğum ağırlıklı yenidoğanlar (n:13,small for gestational age:SGA) 2)normal gebelik ve gebelik haftasına göre fazla doğum ağırlıklı yenidoğanlar (n:19, large for gestational age:LGA) 3)Preeklamptik anneden doğan gebelik haftasına göre normal ağırlıklı yenidoğanlar (n:12, appropriate for gestational age:AGA)) 4)kontrol grup: preeklampsi ve herhangi bir hastalığı olmayan anneden doğan gebelik haftasına göre normal ağırlıklı yenidoğanlar (n:11).Kanlar umblikal kordondan ve postnatal 4.saatte periferal venden toplandı. Serum endoglin düzeyleri ELISA kit kullanılarak ölçüldü.
Bulgular: Endoglin çalışılan tüm umblikal kord ve yenidoğan serumlarında saptandı. Fetal ve erken postnatal serum endoglin düzeyleri arasında SGA, LGA, preeklamptik ve kontrol grupları bakımından fark saptanmadı. Fetal ve erken postnatal serum endoglin düzeyleri SGA grupta AGA gruptan yüksek saptandı.
Sonuçlar: Fetal ve erken postnatal serum endoglin düzeyleri yenidoğanlarda değişmemektedir. SGA yenidoğanlarda serum endoglin düzeyleri farklılık göstermektedir. Sonuçlarımız artan endoglin düzeylerinin SGA patofizyolojisinde rol oynayabileceğini düşündürmektedir.Normal ve komplike gebeliklerden doğan yenidoğanlarda endoglinin fetal büyümedeki rolünu belirlemek için geniş serili çalışmalara ihtiyaç vardır.

 

Anahtar Kelimeler

• Endoglin,fetal büyüme,preeklampsi

The relation of fetal and early postnatal serum endoglin levels with birth weight and maternal preeclampsia

Öz

Aim: The aim of the present study was to evaluate the role of fetal and early postnatal serum endoglin levels in fetal growth and to investigate the association between neonates of preeclamptic mothers and endoglin levels.
Material and Methods: Fiftyfive neonates were prospectively enrolled into the study and divided into four groups: 1) Normal pregnancy and small for gestational age (SGA) neonates (n:13), 2) normal pregnancy and large for gestational age (LGA) neonates (n:19), 3) appropriate for gestational age (AGA) neonates of preeclamptic mothers (n:12), and 4) control group: AGA neonates born to mothers without preeclampsia or any other disease (n:11). Blood was collected from umbilical cords (UC) with both ends clamped, and from peripheral vein in the postnatal 4th hour. Serum endoglin levels were measured by employing an ELISA kit.
Results: Endoglin was detectable in the serum of all studied umbilical cord and neonates. No statistically significant differences were found between fetal and early postnatal serum endoglin levels in SGA, LGA, preeclamptic and control groups. Fetal and early postnatal serum endoglin levels of SGA group were significantly higher than the values of AGA group.
Conclusion: Fetal and early postnatal serum endoglin levels seem to be unchanged in neonates.We showed that SGA neonates are characterized by a alterations in serum endoglin levels.Our results suggest that increased endoglin levels may play a role in the pathophysiology of SGA. Further studies with larger patient series are required to determine the role of endoglin in fetal growth in normal neonates and in neonates born after a complicated pregnancy.

 

Anahtar Kelimeler

• Endoglin,fetal growth,preeclampsia

Kaynakça

1. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837-42.
2. Chedraui P, Lockwood CJ, Schatz F, Buchwalder LF, Schwager G, Guerrero C, Escobar GS, Hidalgo L. Increased plasma soluble fms-like tyrosine kinase and endoglin levels in pregnancies complicated with preeclampsia. J Matern Fetal Neonatal Med ; 22: 565-70. Gregory AL, Xu G, Sotov V, Letarte M. Review: the enigmatic role of endoglin in the placenta. Placenta 2014; 35: 93-9.
3. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-87.
4. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992
5. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki- Tovi S, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor Stepan H, Krämer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007; 92: 2831-4.
6. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab ; 90: 4895-903. with small-for
7. Åsvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol 2011; 173: 630-9.
8. Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol ; 197: e1-6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating angiogenic factors and the risk of preeclampsia.N Engl J Med 2004; 350: 672-83.

9. Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3.Am J Pathol ; 172: 77-85. Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A.Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008; 29: 555-63.
10. Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci 2007; : 51-7.
11. Lim JH, Kim SY, Park SY, Lee MH, Yang JH, Kim MY, Chung JH, Lee SW, Ryu HM. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia. Prenat Diagn ; 29: 471-6. Staff AC, Harsem NK, Braekke K, Hyer M, Hoover RN, Troisi R. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies. Eur J Obstet Gynecol Reprod Biol 2009; 143: 29-33.